Compare EOG Resources Inc (EOG) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EOG Resources Inc vs Summit Therapeutics Inc — how do they compare? EOG Resources Inc trades at $142.77 (market cap $75.22B), while Summit Therapeutics Inc trades at $15.2 (market cap $12.06B). The key difference: EOG Resources Inc is far larger — about 6.2× Summit Therapeutics Inc's market cap, and EOG Resources Inc pays a 2.85% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| EOG | SMMT | |
|---|---|---|
Market Cap | $75.22B | $12.06B |
Sector | Energy | Health |
52-Week High | $149.89 | $26.98 |
52-Week Low | $101.78 | $12.55 |
Enterprise Value | $78.56B | $11.39B |
Dividend Yield | 2.85% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EOG Resources trades at $142.4, up 0.13% today, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 25.81% net income margin and a low P/E of 11.16. Recent Q2 2026 earnings of $5.07 per share beat estimates, driven by higher oil prices and production. Analyst consensus is a Buy with a $157.88 price target, and institutional interest remains positive.
The outlook for EOG is favorable, supported by consistent earnings beats, shareholder returns via dividends, and a disciplined growth strategy. Key risks include oil price volatility and capital expenditure outflows. The stock presents a value opportunity with upside potential, but investors should monitor energy market trends and execution on international projects.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EOG Resources Inc
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
